Loading viewer...
conference
Format: PDF conference
Aethlon Medical presented its immunotherapeutic platform focused on cancer and infectious disease treatment at the LD Micro Invitational XIII Conference. The company highlighted its first-in-class Hemopurifier device, which has demonstrated exosome and circulating virus capture in clinical trials and received FDA Breakthrough Device designation for two indications. Aethlon maintains a solid financial position with no debt and is advancing clinical development of its lead therapeutic technology.
presentation
conference
26 Pages
Franco-Nevada
ANZ 2024 ESG Investor Forum - Environmental & Social Governance
conferenceconference
45 Pages
ANZ Group Holdings Limited